Metrics cut 1
- Crop Health demerger timeline pushed to ~March 2027 (from December 2026), delayed 2-3 months due to fundraise
Event Participants
Executives
4 Raju Nannapaneni, Amit Parekh, Rajesh Chhabiam, Rajiv Menon
Analysts
11 Abhigyan Srivastava, Aman, Arjun, Hrishikesh Patole, Kunal Randeria, Pranav Chawla, Rashmmi Shetty, Sahil Mahajan, Santosh, Tanya Chaudhary, Vamsi Krishna Hota
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹794.4 crores | Down ~43% YoY from ₹1,390.6 crores; decline driven by lower lenalidomide (Revlimid) revenue, partially offset by double-digit base business growth |
| EBITDA | ₹245.7 crores (30.9% margin) | Margin improved QoQ on higher international/domestic contribution and measured operating costs |
| PAT | ₹206.5 crores | vs ₹269 crores in Q4 FY26 (which included ₹115 crores one-time deferred tax remeasurement benefit); normalized PAT grew 24% QoQ |
| Associate (Adcock Ingram) Revenue | ₹1,582.8 crores | Associate PAT ₹242.2 crores; Natco share ₹84.3 crores at 35.75% stake |
| Domestic Formulation Revenue | ₹136 crores | Up from ~₹107 crores quarterly base run-rate; management guides +25% domestic growth for FY27 |
| Brazil Revenue | ₹178 crores | +180% YoY growth; driven by oncology portfolio |
| Canada Revenue | ~₹56 crores | Part of international formulation business (₹477 crores total) |
| Net Cash | ~₹1,400 crores | After ~₹3,000 crores deployed last year (primarily Adcock stake acquisitions); before planned ₹2,000 crores fundraise |
| Stakes in Adcock Ingram | 49.0% | Raised from 35.75% via additional 13.25% acquisition in July 2026 |
Geographic & Segment Commentary
India (Domestic Formulation): Revenue of ₹136 crores in Q1, up from ₹107 crores base business run-rate. Growth driven by semaglutide brand (₹2 crores/month), oncology segment, and third-party orders. Management expects ~25% domestic growth for FY27.
Brazil: Revenue of ₹178 crores, up 180% YoY. Oncology pipeline driving strong growth, with additional meaningful launches expected in CY27 subject to patent litigation outcomes. Company anticipates continued strong growth in this geography.
Canada: Sales of ~₹56 crores in the quarter. Part of the international formulation business (₹477 crores total); management identifies Canada as one of three key growth geographies along with Brazil and US.
South Africa (Adcock Ingram): Revenue ₹1,582.8 crores with PAT ₹242.2 crores; Natco's share at 35.75% was ₹84.3 crores. Q1 benefited from a strong flu season. Natco increased stake to 49% in July 2026 and has filed 3 dossiers for registration (typical 18-24 month timeline), with Natco-sourced products expected in market around 2028.
US: Revlimid contribution negligible in Q1. Two launches planned in next financial year (FY28), one of which is Carfilzomib (calendar 2027 launch, on track). FTF target of 2-3 for the current year.
Crop Health Sciences: Q1 revenue ₹40 crores with an EBITDA loss; seasonal loss expected. Portfolio has grown to ~35 products with 8 CTPR-related products (30-35% of revenue). El Niño-related delayed rains impacted Q1; Q2 (strongest quarter) expected to be significantly better. Targeting breakeven for FY27.
Company-Specific & Strategic Commentary
Adcock Ingram Consolidation: Increased stake to 49% via ₹1,064 crores investment in July 2026; management stated willingness to acquire more if Bidvest (51% holder) offers, noting first right of refusal. Synergies include pipeline sourcing from Natco and relationships with Indian partners. Three dossiers filed for South Africa registration targeting ~2028 market entry.
Fundraise for M&A: Board approved ₹2,000 crores raise (QIP/rights/other options being evaluated). Cash deployed: ~₹3,000 crores on Adcock acquisitions over last year. Management citing two acquisition opportunities - one in India, one outside - plus short-term loan repayment (₹1,400 crores net cash current) and ₹250-300 crores annual organic CapEx.
R&D Pipeline Strategy: Internal target of 8-10 filings/year with 2-3 FTFs; 70-80% of R&D spend directed at products launching between 2028-2035. Management emphasized long-term return profile: earliest launches (12 months out) yield 15-20% returns, while 8-9 year-out products can yield 20-40x returns.
eGenesis Innovation Asset: Xenotransplantation platform has transplanted pig kidneys into multiple patients; 2 patients survived 8+ months. Management called it the "most exciting" and "most valuable" of 4 innovation assets, with updates expected in coming months.
Crop Health Demerger: Demerger plans remain active but delayed by 2-3 months due to the fundraise; expected completion now ~March 2027 instead of December 2026.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Domestic formulation growth | ~25% YoY for FY27 | Driven by semaglutide brand, oncology, and third-party orders; base business maintained at ~₹107 crores/quarter |
| Crop Health Sciences | Breakeven for FY27 | Q1 seasonal loss; Q2 significantly better (strongest agro quarter); El Niño delayed rains were key Q1 factor |
| Adcock Ingram contribution | ~₹750 crores (maintained) | Normal run-rate ~₹100 crores/quarter; Q1 flu season bump not sustainable; guidance unchanged |
| Consolidated gross sales | ₹3,300-3,400 crores for FY27 | Growth from US, Brazil, Canada; management expects all three geographies to contribute |
| Carfilzomib launch | Calendar 2027 | On track; plant upgrade completion by end of 2026; launch date confidential |
| US launches | 2 launches in FY28 | Exclusivity-related; molecule names confidential |
| FTF filings | 2-3 FTFs in FY27 | Part of 8-10 total annual filings target |
| Crop Health demerger | ~March 2027 (delayed from December) | Delayed 2-3 months due to fundraise process |
Risks & Constraints
| Risk | Context |
|---|---|
| Revlimid revenue decline | Lenalidomide contribution negligible in Q1 vs material prior year; largely expected given competitive landscape. Management positioning base business (up double-digit) to offset. |
| Dependence on Adcock Ingram | 35-40% of quarterly earnings from associate; Q1 benefited from flu season bump (~₹84 crores vs normal ₹35-40 crores quarterly at 35.75% stake). Management guides ~₹100 crores/quarter normal run-rate; seasonal volatility remains. |
| Crop Health weather/seasonality | El Niño fears and delayed rains disrupted Q1 cropping season; Q2 is the strongest quarter and management expects it to "significantly" improve. FY27 breakeven target dependent on Q2-Q3 performance. |
| Semaglutide pricing competition | Intense competition in India; market "fairly conservative" with pricing stability expected in "next few months". Brand generating ~₹2 crores/month, currently not profitable. Third-party business not repeatable. |
| Olaparib litigation | Trial scheduled within next few months; exclusivity determination pending (30-month clock exceeded). Two open questions - monetary damages and exclusivity - both undecided. |
| Tax rate volatility | Consolidated rate swings with geographic mix; Brazil (higher tax regime) contributed more this quarter, pushing rate up. India rate ~27% post-new regime; global rate country-dependent. |
| Fundraise dilution | ₹2,000 crores equity raise (QIP/rights/other) will dilute existing shareholders; individual investors have requested rights route. Management evaluating all options. |
Q&A Highlights
Export Revenue & Geographic Mix
- Question: Asked for constant-currency growth across Canada and Brazil, and the reason for ~14% QoQ decline in export sales (Vamsi Krishna Hota, ASK)
- Answer: Brazil at ₹178 crores (+180% YoY) and Canada ~₹56 crores. QoQ decline attributed to seasonal/cyclical order timing across products and geographies; management advised focusing on annual guidance rather than quarterly granularity (Amit Parekh, Rajesh Chhabiam). Management noted the earnings bump came from Adcock (flu season), not the Indian entity.
R&D Spend & Expense Run-rate
- Question: Asked the reason for sharp decline in other expenses and whether the current run-rate is sustainable (Kunal Randeria, Axis Capital)
- Answer: Last year Q1 had high R&D spend (milestones, exhibit batches, clinical trials) and higher legal costs. Current quarter is lower but "cannot be the run rate" - R&D is lumpy, planned around cash flow, and will be higher going forward. Annual approach recommended (Amit Parekh, Rajesh Chhabiam).
Crop Health Sciences - Breakeven & Portfolio
- Question: Asked whether Crop Health has broken even, and FY27 revenue guidance (Rashmmi Shetty, Dolat Capital)
- Answer: Q1 was an EBITDA loss due to El Niño-delayed rains; company still targeting FY27 breakeven. Last year Crop Health revenue was ₹138 crores; Q1 came in at ~₹40 crores. Q2 (strongest agro quarter) will give clearer picture. Portfolio now has ~35 products; CTPR represents ~30-35% of revenue with 8 out of 35 products being CTPR-related. Fungicide brand Glance (limited competition) performing well (Rajesh Chhabiam).
Adcock Strategic Rationale & Synergies
- Question: Asked about plans to improve growth/profitability in South Africa post-stake increase (Tanya Chaudhary, Investec); and timing for launching Natco products in Adcock (Pranav Chawla, JMAC)
- Answer: Two key synergies: (1) pipeline from Natco into Adcock's South Africa distribution, (2) relationships with Indian partner companies to source additional pipeline. Adcock provides earnings stability and diversification - "35-40% of our earnings are coming from Adcock" this quarter. Three dossiers already filed; registration typically takes 18-24 months, so products expected ~2028 (Rajesh Chhabiam).
Fundraise & M&A
- Question: Rationale for ₹2,000 crores fundraise despite ~₹1,400 crores net cash; asked for M&A color and CapEx guidance (Vamsi Krishna Hota, ASK; Pranav Chawla, JMAC; Aman, individual investor)
- Answer: Cash position after spending ~₹3,000 crores on Adcock stakes last year; evaluating 2 acquisition opportunities (one India, one outside India). Funds also for short-term loan repayment and organic CapEx of ₹250-300 crores/year. Management confirmed exploring QIP, rights issue, and other options; no geographic-specific allocation disclosed (Amit Parekh). Individual investor requested rights issue consideration - management acknowledged and said board is exploring all options (Rajesh Chhabiam).
US Pipeline - Carfilzomib, Olaparib & FTF
- Question: Asked about Carfilzomib launch timing, Olaparib litigation status, and FTF filings expected over next 2 years (Abhigyan Srivastava, Miraculous Investment Managers; Hrishikesh Patole, 361 Capital)
- Answer: Carfilzomib launch on track with plant upgrade completing end of 2026; launch date confidential. Olaparib: trial date set for "next few months" (exact date not disclosed), plus pending exclusivity determination since the 30-month period was exceeded. FTF target of 2-3 this year; overall 8-10 filings/year (Rajesh Chhabiam).
Semaglutide - India & South Africa
- Question: Asked about domestic semaglutide profitability and South Africa launch timing (Tanya Chaudhary, Investec; Arjun, individual investor)
- Answer: India brand doing ~₹2 crores/month; "doesn't lose money but doesn't make much money" - market still settling with intense competition, pricing stability expected in coming months. South Africa: approval still "a little away", exploring third-party vendor options to accelerate launch; a competitor already received approval (Rajesh Chhabiam).
eGenesis Innovation Update
- Question: Asked for updates on innovation assets (Hrishikesh Patole, 361 Capital)
- Answer: eGenesis is the biggest bet - multiple patients transplanted with pig kidneys, 2 patients survived 8+ months. Called the "most exciting" and "most valuable" of the 4 innovation assets; expecting "very exciting updates" in next few months (Rajesh Chhabiam).
Key Takeaway
Natco Pharma reported a weak revenue quarter (₹794.4 crores, down ~43% YoY) as Revlimid contribution turned negligible, but normalized PAT grew 24% QoQ to ₹206.5 crores on improved margins (EBITDA 30.9%) and strong associate performance - Adcock Ingram delivered ₹84.3 crores in profit share (35.75% stake) boosted by a South African flu season, with the stake now raised to 49% in July 2026. Strategic focus centers on Adcock synergy realization (3 dossiers filed, ~2028 market entry), a ₹2,000 crores fundraise for two identified M&A targets (one India, one overseas), and R&D pipeline building toward 2-3 FTF filings this year and 8-10 total annual filings. Guidance maintained: domestic growth ~25%, Crop Health breakeven, consolidated gross sales of ₹3,300-3,400 crores, and ~₹750 crores Adcock contribution. Management reiterated this is a "long haul" business - 70-80% of R&D spend targets 2028-2035 launches, with Carfilzomib (CY27) and Olaparib litigation outcomes as near-term catalysts, while watching semaglutide pricing stabilization, El Niño agro seasonality, and fundraise dilution risks.
Transcript incomplete - the provided transcript contains all standard sections (financial highlights, Q&A), but the Q&A section appears truncated at the end (no further questions after Aman's query) and some participant names were not fully captured. Financial details for certain segments (e.g., rest-of-world export split) were not disclosed during the call.